Cyteir Therapeutics, Inc. (CYT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Lexington, MA, アメリカ. 現CEOは Markus F. Renschler.
CYT を有する IPO日 2021-06-18, 46 名の正社員, に上場 NASDAQ Global Select, 時価総額 $108.71M.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
